Economic evaluation alongside the Speed of Increasing milk Feeds Trial (SIFT)

Warda Tahir, Mark Monahan, Jon Dorling, Oliver Hewer, Ursula Bowler, Louise Linsell, Christopher Partlett, Janet Elizabeth Berrington, Elaine Boyle, Nicolas Embleton, Samantha Johnson, Alison Leaf, Kenny McCormick, William McGuire, Ben J Stenson, Ed Juszczak, Tracy E Roberts

ABSTRACT

Objectives To evaluate the cost-effectiveness of two rates of enteral feed advancement (18 vs 30 mL/kg/day) in very preterm and very low birth weight infants.

Design Within-trial economic evaluation alongside a multicentre, two-arm parallel group, randomised controlled trial (Speed of Increasing milk Feeds Trial).

Setting 55 UK neonatal units from May 2013 to June 2015.

Patients Infants born <32 weeks’ gestation or <1500 g, receiving less than 30 mL/kg/day of milk at trial enrolment. Infants with a known severe congenital anomaly, no realistic chance of survival, or unlikely to be traceable for follow-up, were ineligible.

Interventions When clinicians were ready to start advancing feed volumes, infants were randomised to receive daily increments in feed volume of 30 mL/kg (intervention) or 18 mL/kg (control).

Main outcome measure Cost per additional survivor without moderate to severe neurodevelopmental disability at 24 months of age corrected for prematurity.

Results Average costs per infant were slightly higher for faster feeds compared with slower feeds (mean difference £267, 95% CI −6928 to 8117). Fewer infants achieved the principal outcome of survival without moderate to severe neurodevelopmental disability at 24 months in the faster feeds arm (802/1224 vs 18 mL/kg (control)).

Main outcome analysis showed a likelihood of worse outcomes for faster feeds compared with slower feeds.

Conclusions The stochastic cost-effectiveness analysis shows faster feeds are broadly equivalent on cost grounds. However, in terms of outcomes at 24 months age (corrected for prematurity), faster feeds are harmful. Faster feeds should not be recommended on either cost or effectiveness grounds to achieve the primary outcome.

INTRODUCTION

The total cost of preterm birth to the public sector is nearly £3 billion over childhood, of which 34% is attributable to very preterm birth before 32 weeks of gestation. Costs arise from increased healthcare resource utilisation such as hospital inpatient and outpatient care, community care and medications. There are also considerable societal costs associated with preterm birth-related morbidities, such as productivity loss resulting from time taken off work by parents and carers and additional expenditure on home adjustments, special equipment and travel. There is uncertainty regarding enteral feeding practices of very preterm and very low birth weight (VLBW; <1500 g) infants. Increasing milk volumes slowly is associated with increased risk of late onset sepsis (LOS), while faster increases may increase the likelihood of necrotising enterocolitis (NEC). In very preterm or VLBW infants, LOS and NEC are important causes of long-term neurodevelopmental disability. Children with neurodevelopmental disabilities require a range of services beyond simply healthcare, such as social services, special educational support and rehabilitation and costs accrue throughout the individual’s lifespan. The Speed of Increasing milk Feeds Trial (SIFT) aimed to address uncertainty in enteral feeding practices by comparing two rates of enteral feed advancement (18 vs 30 mL/kg/day) in very preterm and VLBW infants. This paper presents the economic evaluation undertaken alongside SIFT.

METHODS

Details of the trial have been published elsewhere. Briefly, 2804 babies were recruited into the trial, of which 1400 were randomised to faster feeds...
and 1404 were randomised to slower feeds. Outcomes were assessed until discharge home from neonatal units and again at age 24 months, corrected for prematurity (see online supplementary material figure S1). Resource use data were collected prospectively from centres participating in the trial. All centres completed a total of eight different data collection forms that included specific items measuring healthcare use. Where serious adverse events were reported, the associated resource use was collected on an additional form by the relevant participating centres. Health service use for the first 2 years of life was also measured through a parent questionnaire, which included healthcare-related resource use items such as use of primary care services and hospital readmissions.

COSTS

A National Health Service and Personal Social Services perspective was adopted; thus, only the direct costs to the health service provider during the trial’s duration were considered. Table 1 presents the relevant items of resource use, their associated unit costs and the source from which these costs were obtained. All costs were expressed in pounds sterling (GBP) and in 2017–2018 prices. Costs were inflated where necessary, using the hospital and community health services index.10 More detail on resource use and disaggregated costs is presented in the online supplementary tables S1 and S2.

ECONOMIC ANALYSIS

A preliminary cost-consequence analysis was conducted to compare the disaggregated costs and outcomes for both feeding increments.14 Mean costs per infant were estimated for each arm and the mean cost differences between the two feeding allocations were calculated. A bootstrapping approach with replacement was undertaken to calculate CIs around the mean costs.12

The primary base case economic analysis took the form of a cost-effectiveness analysis, a method for assessing the gains in health relative to the costs of the different health interventions.15 Costs and clinical outcomes associated with each feeding allocation were combined by calculating incremental cost-effectiveness ratios (ICERs). Cost data were discounted at 3.5% but discounting is not applied to outcomes in natural units. Cost-effectiveness was based on the principal outcome of additional cost per survivor without disability at 24 months corrected age.

STOCHASTIC COST-EFFECTIVENESS ANALYSIS

A stochastic cost-effectiveness analysis (PSA) was conducted on the base-case results. The approach taken in the PSA is that all important variables relating to costs and clinical outcomes are given a distribution that describes the uncertainty surrounding the mean. The distributions are simulated 5000 times. Each time, random numbers are drawn from the appropriate distributions. After each simulation, the incremental costs and effects are plotted in a cost-effectiveness plane which comprises four quadrants: north-east (NE), north-west (NW), south-east (SE) and south-west (SW). The scatterplot that is produced represents the simulations. If dots from the scatterplot are in the NE quadrant, this indicates that the intervention is more costly and more effective compared with the comparator (slower feeds). Dots in the NW quadrant indicate that the intervention is more costly and less effective than the comparator. Based on these simulations, the probability that the intervention would be cost-effective is presented. This is the standard approach for health economics following accepted guidelines (CHEERS).16 and is a presentation of results of cost-effectiveness studies which would be required by decision-makers such as NICE.17

Results were also presented using cost-effectiveness acceptability curves (CEACs) to reflect sampling variation and

| Table 1 Unit costs of resource items (2017–2018 prices) |
|---------------------------------|-----------------|----------------|
| Resource use items            | Unit cost (£)*  | Source         |
| Intervention                   |                 |                |
| Cost per day on parenteral nutrition | 45             | Walter et al 24 |
| Intensive care                 |                 |                |
| Cost per day in intensive care (differentiated by level of care required) | 1295           | NHS Reference Costs 26 |
| Level 1—Intensive Care         | 1295            |                 |
| Level 2—High Dependency Care   | 1032            |                 |
| Level 3—Special Care           | 510             |                 |
| Initial hospital stay          |                 |                |
| Cost per pulmonary haemorrhage | 1485            | NHS Reference Costs 29 |
| Cost per IVH by severity       |                 |                |
| Grade 1 IVH/Germinial matrix haemorrhage | 862            | NHS Reference Costs 29 |
| Grade 2 IVH                     | 1472            | NHS Reference Costs 29 |
| Grade 3/4 IVH                   | 1519            | NHS Reference Costs 29 |
| Course of shunts for hydrocephalus | 2608           | NHS Reference Costs 29 |
| Bronchopulmonary dysplasia      | 5954            | NHS Reference Costs 29 |
| Periventricular leukomalacia     | 1341            | NHS Reference Costs 29 |
| Retinopathy treated medically or surgically | 1603           | NHS Reference Costs 29 |
| PDA treated with NSAID          | 1152            | BNFC 30        |
| Surgeries due to gut signs      | 6629            | NHS Reference Costs 29 |
| Cost of antibiotic medication per day | 3.00          | BNFC 30        |
| Cost of antifungal treatment per day | 1.06          | BNFC 30        |
| Cost per mL of Preterm milk formula | 0.02          | Ganapathy et al 31 |
| Cost per packet of breast milk fortifier | 0.93      | Ganapathy et al 31 |
| Cost per litre of donor breast milk | 335            | Renfrew et al 32 |
| Cost per 200 mL of term formula milk | 2.00          | Renfrew et al 32 |
| Cost per other health professional visit | 135       | NHS Reference Costs 29 |

*Inflated to 2017–2018 costs using the UK hospital and community health services pay and prices index. Costs were assigned using a macrocosting (top-down) approach.15
GP, general practitioner; IVH, intraventricular haemorrhage (intracranial abnormality); NSAID, non steroidal anti-inflammatory drugs; PDA, patent ductus arteriosus.
uncertainties in the cost-effectiveness value where appropriate. A CEAC shows the probability that an intervention (eg, faster feed increments) is cost-effective compared with the alternative (eg, slower feed increments), given the observed data, for a range of maximum monetary values (thresholds) that decision-makers might be willing to pay for a particular unit change in outcome. We examined cost-effectiveness across a range of monetary willingness to pay thresholds, 0–£40 000 per additional survivor without disability at 24 months corrected age. To account for missing resource use data where follow-up data were not available, multiple imputation was performed following published and widely implemented methodology. We used the multiple imputation technique of predictive mean matching to impute the missing values for total costs at 2 years. The imputation model was based on treatment group, and used M=20 imputed datasets.

RESULTS
Participants
A total of 2804 infants were recruited, 1400 of which were randomised to faster feeds and 1404 to slower feeds. The proportions of infants withdrawn from the trial or lost to follow-up are presented in online supplementary figure S1. The data on the primary outcome at 24 months were available in 1224 (87.4%) of the faster group and 1246 (88.7%) of the slower group. The primary base case analysis comprised of only those infants for whom there were complete outcome data.

Resource use and costs
The number of parents who fully completed the resource use questionnaire was 842/1224 (68.8%) and 873/1246 (70%) in the fast and slow feeding increment arms of the trial, respectively. The mean costs for each group are presented in table 2. The cost for faster feeds was, on average, an estimated £242 less per infant (95% CI −6307 to 6251) than slower feeds during infants’ initial hospital stay. However, during the 2 year follow-up, the faster increment group was more costly, on average, by approximately £510 (95% CI −2864 to 4508) per infant. In terms of costs up to 24 months, faster feeds were slightly more costly, on average, £267 (95% CI 6928 to 8117) per infant.

Cost-consequence analysis

In terms of overall costs, the average cost per infant for faster feeds was slightly more costly than slower feeds (mean difference £267, 95% CI −6928 to 8117).

Although there were fewer deaths in the faster feed group, the primary outcome of survival without moderate or severe neurodevelopmental disability at 24 months corrected age, the intervention (faster feeds) was less effective than the comparator (slower feeds). Increasing milk feeds at a faster rate was associated with 46 (2.6%) more infants with moderate to severe disability compared with the slower feed group (mean difference: 0.96, 95% CI 0.92 to 1.01).

The breakdown of costs shows that faster feeds compared with slower feeds is slightly less costly, on average, during infants’ initial hospital stay, but in the postdischarge period up to 24 months, the 2-year follow-up data show that costs are greater in those allocated faster increments, on average. This resulted in a slightly higher mean total cost per infant in the intervention arm (faster feeds). This is due to greater resource use associated with faster increments, in terms of hospital inpatient stays and primary care visits in the postdischarge period (online supplementary table S1 and S2).

Cost-effectiveness analysis
Faster feeds are shown to cost more per infant on average and are also less effective in achieving the primary outcome; thus, they are dominated by the comparator (slower feeds) (see table 2, table 3, figure 1). There is therefore no ICER to present in this circumstance.

Stochastic cost-effectiveness analysis
The cost-effectiveness plane for the base-case analysis is presented in figure 1. The majority of the scatterplots (depicting paired incremental costs and outcomes) are in the NW and SW quadrants. Scatterplots falling in the NW quadrant represent higher cost and worse outcome than the comparator, while scatterplots in the SW quadrant represent worse outcome and lower costs. Thus, figure 1 suggests that faster feed increments are a less effective intervention. However, it is uncertain whether faster feeds are likely to be more costly (NW) or less costly (SW) relative to slower feed increments. The CEAC (figure 2) shows the probability of faster feeds being cost-effective at various values of decision-makers’ willingness-to-pay per additional survivor without moderate to severe disability at 24 months of age (corrected for prematurity). The CEAC (figure 2) suggests that the probability of the intervention being cost-effective is less than 50% for all willingness to pay values. In addition, the

<table>
<thead>
<tr>
<th>Cost category</th>
<th>Total cost (n=1224)</th>
<th>Mean (n=1224)</th>
<th>SD (n=1224)</th>
<th>Total cost (n=1246)</th>
<th>Mean (n=1246)</th>
<th>SD (n=1246)</th>
<th>Bootstrap mean difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costs of initial hospital care</td>
<td>124 386 552</td>
<td>101 623*</td>
<td>80 759</td>
<td>12 923 790</td>
<td>101 865</td>
<td>80 498</td>
<td>−242 (−6307 to 6251)</td>
</tr>
<tr>
<td>Costs from initial discharge to hospital up to 24 months corrected age</td>
<td>10 151 856</td>
<td>8294</td>
<td>49 585</td>
<td>9 698 864</td>
<td>7784</td>
<td>38 473</td>
<td>510 (−2864 to 4508)</td>
</tr>
<tr>
<td>Total costs of health service use after initial discharge from hospital and up to 24 months corrected age</td>
<td>134 538 408</td>
<td>109 917</td>
<td>98 040</td>
<td>13 623 900</td>
<td>109 650</td>
<td>94 788</td>
<td>267 (−6928 to 8117)</td>
</tr>
</tbody>
</table>

*Mean total costs are calculated as total cost for this category divided by the sample size of the arm (eg, 124 386 552/1224 for costs of initial hospital care in the faster feeding arm).
†Total costs are the sum of costs of initial hospital care and costs from discharge up to 24 months corrected age.


140.254.116.125 On: February 5, 2021 At: 10:30PM
probability of cost-effectiveness decreases as the willingness to pay increases.

Mean total costs for all infants, adjusting for missing data using multiple imputation, are found in the online supplementary table S3. When the missing values were accounted for, faster feed increments remain more costly in comparison to slower feed increments but at a slightly higher level (£378 more) per feed increments. However, in terms of the clinical outcomes, faster feeds were less effective than slower feeds (18 mL/kg/day) in achieving the principal outcome of survival without moderate or severe neurodevelopmental disability at 24 months corrected age. Fewer infants in the faster increments arm achieved the primary clinical outcome (n=802) compared with the slower increment arm (n=848).

When the uncertainty around all the estimates is incorporated into the analysis, the results suggest that the faster feeding increment is dominated by the slower feeding increment, as it is on average more costly and less effective than the slower increment. The cost-effectiveness plane (figure 1) which incorporates the uncertainty around each point estimate in the results shows that relative to the comparator, faster feeding increments are likely to be less cost effective than slower feeding increments (with the scatter plot being predominantly to the left of the origin in figure 1). The CEAC also shows the low probability of the intervention being cost-effective, which clearly decreases as the willingness to pay increases. Thus, in summary, for very preterm or VLBW infants, a faster rate (30 mL/kg/day) is probably more costly, on average, at 2 years corrected age and clearly less effective, with fewer infants achieving the principal outcome of survival without moderate or severe neurodevelopmental disability at 24 months corrected age. Fewer infants in the faster increments arm achieved the primary clinical outcome (n=802) compared with the slower increment arm (n=848).

One of the key principles of health economic analysis is to maximise the health benefits from, and ensure the most efficient allocation of, scarce resources. It is plausible to incur analyses that suggest a potentially small decrement in the health outcome if the saved resources can be used to better effect a faster rate (30 mL/kg/day) are per infant more costly and less effective in comparison to a slower rate (18 mL/kg/day).

In terms of initial hospital and postdischarge costs between the two feeding increments evaluated, a faster increment (30 mL/kg/day) was shown to be slightly more costly, on average, compared with feeding with a slower increment (18 mL/kg/day) at 2 years corrected age. The average cost per infant for faster increments was £109 917 compared with £109 650 for slower increments. However, in terms of the clinical outcomes, faster feeds were less effective than slower feeds (18 mL/kg/day) in achieving the principal outcome of survival without moderate or severe neurodevelopmental disability at 24 months corrected age.


© Copyright BMJ Publishing Group Ltd

<table>
<thead>
<tr>
<th>Costs/Consequences</th>
<th>Faster increments (n=1224)</th>
<th>Slower increments (n=1246)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total costs of health service use for 2 years</td>
<td>£134 538 408</td>
<td>£136 623 900</td>
</tr>
<tr>
<td>Costs of initial hospital care</td>
<td>£124 386 552</td>
<td>£126 923 790</td>
</tr>
<tr>
<td>Costs from initial discharge from hospital up to 24 months corrected age</td>
<td>£10 151 856</td>
<td>£9 698 864</td>
</tr>
<tr>
<td>Survival at hospital discharge</td>
<td>1332/1394 (95.7%)</td>
<td>1337/1399 (95.23%)</td>
</tr>
<tr>
<td>Death before discharge home</td>
<td>60/1392 (4.3%)</td>
<td>65/1393 (4.7%)</td>
</tr>
<tr>
<td>Survival without moderate or severe neurodevelopmental disability at 24 months</td>
<td>802/1224 (65.5%)</td>
<td>848/1246 (68.1%)</td>
</tr>
<tr>
<td>Survival (at 24 months, corrected age)</td>
<td>1326/1394 (95.1%)</td>
<td>1322/1399 (94.5%)</td>
</tr>
<tr>
<td>Moderate to severe neurodevelopmental disability</td>
<td>473/1394 (33.9%)</td>
<td>405/1399 (28.9%)</td>
</tr>
<tr>
<td>Neonatal late onset invasive infection (LOII)</td>
<td>414/1389 (33.9%)</td>
<td>434/1397 (31.1%)</td>
</tr>
<tr>
<td>NEC</td>
<td>70/1394 (5.0%)</td>
<td>78/1399 (5.6%)</td>
</tr>
</tbody>
</table>

Disability was defined as moderate/severe in any of the following categories any of: moderate/severe visual impairment, moderate/severe hearing impairment, moderate/severe gross motor impairment or moderate/severe cognitive impairment. NEC, necrotising enterocolitis.

Figure 1 Cost-effectiveness plane (fast vs slow feeds). NW, north-west; SE, south-east; SW, south-west.

Figure 2 Cost-effectiveness acceptability curve (fast vs slow feeds). SIFT, Speed of Increasing milk Feeds Trial.
elsewhere. However, this interpretation does not apply in the current analysis due to uncertainty in a number of areas. First, regarding costs, the PSA and, in particular, the cost-effectiveness plane suggests that faster feeds could be either more or less costly, compared with slower feeds. Second, with respect to the clinical effectiveness, the PSA represented in the cost-effectiveness plane (figure 1) indicates a potential risk for harm associated with the faster feeding increment relative to the slower feeding increment based on the distribution of the data at 24 months. All data points are presented in either the NW (more costly, less effective) or SW (less costly, less effective) quadrants. Finally, impaired development at 2 years is a serious outcome associated with life-long consequences and increased costs across a number of sectors including education, healthcare and social care.2

There are also broader societal consequences that could result from the clinical outcome, namely productivity loss, stemming from both time off work and the lost earnings of parents of children with disabilities.1–19 The trial did not collect resource and outcome data beyond 2 years.

It is noteworthy that while the costs of initial hospital care were lower in those allocated faster increments compared with those allocated slower increments, in the specific period from initial discharge up to 2 years corrected age, the costs incurred by those allocated faster increments were greater overall, per infant, compared with those allocated to slower increments, potentially revealing problems as the infants mature.

In summary, based on neurodevelopmental outcomes at 2 years, and given the uncertainty in both the cost and clinical effectiveness, the faster feeding increment (rate 30 mL/kg/day) that was tested in the trial cannot be advocated on cost-effectiveness grounds.

Strengths and limitations of the study

Strengths of the economic evaluation include that it is the first, conducted alongside a randomised controlled trial (RCT) comparing enteral feeding practices in infants. SIFT is the largest study of any infant feeding intervention ever undertaken in the neonatal age group and thus there is broad applicability of this economic evaluation, for both policy and practice. The resource use and outcome data were prospectively collected at different points in the trial. Unit costs were obtained from standard and recognised sources. The cost effectiveness results also benefited from the robustness of the main analyses and stochastic analyses.20

A previous clinical systematic review21 identified only four RCTs comparing enteral feed volumes in very preterm and VLBW infants. All reviewed studies had a very short follow-up period (2 weeks),22 or no follow-up at all.23,24 Furthermore, none of these studies included economic evaluations; thus, conclusions could not be made regarding the most cost-effective feeding strategy.

A limitation of this study is that the follow-up period was only 2 years. A longer follow-up would have provided greater scope for observation of the economic consequences of enteral feeding strategies. In particular, the costs and consequences of the disabilities/impairments present and the degree of differentiation in health service use between the two feeding groups would have been informative. Recall bias is another potential limitation as follow-up data were reliant on parent recall over a 24-month period.

Our analyses required some pragmatic assumptions regarding proportions of milk volumes and antibiotic usage during infants’ initial hospital stay due to excessive staff burden in data collection. Nonetheless, our assumptions are supported by existing literature and guidelines, and the relatively low cost impact is unlikely to have any significant impact on the results.

A further potential limitation of this study is the confusion that might arise given that the reported clinical results showed faster feeds were not statistically significantly different from slower feeds for the primary outcome of survival without moderate or severe disability at 24 months (corrected for prematurity),20 whereas the health economics analysis suggests that faster feeding increments cannot be supported on cost-effectiveness grounds as a result of uncertainty in both the costs and outcomes. This contrasting interpretation of the results relates to a requirement in the recommendations for health economic analysis to estimate and quantify the uncertainty around the clinical endpoints using PSA.21 This recommended and widely endorsed approach to conducting robust economic analysis is recognised as potentially challenging and has been widely debated and explained elsewhere.22–26

CONCLUSION

Based on the results of this within-trial economic evaluation, increasing milk feed volumes at the faster rate (30 mL/kg/day) in very preterm or VLBW infants is not a cost-effective strategy and cannot be recommended.

This work highlights an ongoing debate and also reveals the impact of the difference in paradigms between the statistical approach and economics approach to analysis.21,27

Author affiliations

1University of Birmingham, Birmingham, UK
2Division of Neonatal-Perinatal Medicine, Dalhousie University—Faculty of Medicine, Halifax, Nova Scotia, Canada
3National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
4National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK
5Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK
6Neonatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
7Department of Health Sciences, University of Leicester, Leicester, UK
8Newcastle University, Newcastle upon Tyne, UK
9University of Leicester, Leicester, UK
10Neonatal Medicine, Southmead Hospital, Bristol, UK
11John Radcliffe Hospital, Oxford, UK
12Centre for Reviews and Dissemination, University of York, York, UK
13Neonatology, Neonatal Unit, Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, UK
14Nuffield Department of Population Health, University of Oxford, Oxford, UK
15Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK

Contributors WT was the lead author of the manuscript and was supervised in this role by TER and MM. This manuscript was written in collaboration with both TER and MM. All other authors contributed to editing and revising the manuscript.

Funding This paper presents independent research commissioned by the National Institute for Health Research (NIHR). Funded by the Health Technology Assessment Programme of the National Institute for Health Research; ISRCTN registration number ISRCTN76463425.

Disclaimer The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the Health Technology Assessment Programme or the Department of Health.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study. N/A.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and the first author’s name, article citation and DOI remain intact.
and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID IDs
Warda Tahir http://orcid.org/0000-0002-4410-1757
Elaine Boyle http://orcid.org/0000-0002-5038-3148

REFERENCES